ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

Myelofibrosis: Diagnosis, Clinical Manifestations, Treatment Approac…

Amy Zhou

How I Treat Anemia in Myelofibrosis

Cleveland Clinic Taussig Cancer Institute

A. Jain

Momelotinib in MF: Insights from SIMPLIFY-1, SIMPLIFY-2, and MOMENTU…

Jeanne Palmer

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Overview of Myelofibrosis: Management, JAK Inhibitor Trials, and Eme…

Akhil Jain

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

Treatment Landscape of JAK Inhibitors in Myelofibrosis

Juliana Schwaab

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

COMFORT-1 Trial Long-Term Follow-Up: Impact of Ruxolitinib on OS for…

Winship Cancer Institute - Emory University

A. Hunter

Year in Review 2024 - Highlights in MPNs and Impact on Practice

Oncology 2024 Year in Review

P. Bose

Myelofibrosis: To JAK Inhibitors and Beyond

Winship Cancer Institute - Emory University

M. J. Hochman